Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & Events > News
A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1
We’re aware of growing concern around insulin supply in the UK, and we want to reassure our community that this is not a general insulin shortage. There is no need to change the type of insulin you use.
New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.
US-based company Vertex have published promising figures from their cell therapy trial, showing advancements in stem cell research.
If you use the Dexcom G6 app on your Android smartphone, the newest Android 16 operating system may disrupt how the app functions.
We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.
Our CEO received the MBE in recognition of her exceptional services to people with type 1 diabetes (T1D).
Breakthrough T1D has helped organise an event hosted by Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
This study is the largest and most comprehensive to date examining human pancreas tissue for signs of viral infection in people with and without type 1 diabetes (T1D).
People living with type 1 diabetes (T1D) across the UK now have more choice in how to manage their condition, with the mylife CamAPS FX app now available on iPhones.
This charitable pledge by the Bukhman Foundation represents the UK’s largest philanthropic commitment towards funding research to accelerate new treatments and a cure for type 1 diabetes.
We have launched a new 10-year strategy aimed at driving significant advancements in type 1 diabetes (T1D) research, treatment, and care.
Read our top takeaways from the ‘Recruiting to medical research programmes and trials – how can we be smarter and more equitable?’ webinar.
Novo Nordisk will stop producing Levemir insulin next year but there are plans in place to help you transition to an alternative.
Researchers funded by Breakthrough T1D in the US have published promising new data that could help to improve islet transplantation for people with T1D.
A new paper co-authored by Breakthrough T1D, Diabetes UK, and Kidney Research UK has identified six themes to tackle diabetic kidney disease.
Sana Biotechnology, a US-based biotech company, has released clinical data showing that the first person receiving engineered islets from deceased donors is now producing insulin without the need for immunosuppressive drugs.
Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.
We’ve awarded four new grants to UK researchers to help improve lives and develop cures for people living with type 1 diabetes.
The fifth Sugarplum Dinner, hosted by Jubie Wigan saw supporters come together to help fund our mission to cure type 1 diabetes and make everyday life better for everyone who faces it.
Actor Rhea Norwood has been announced as the newest ambassador for Breakthrough T1D.
The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.
Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.
Professor David Baker, a Breakthrough T1D-funded researcher at the University of Washington, has been awarded a Nobel Prize in Chemistry.
Breakthrough T1D will continue JDRF's journey, accelerating breakthroughs in research, breakthroughs in access to treatments, and bringing the T1D community together to help everyone make their own personal breakthroughs.
A new study, which we helped conduct, reveals the most important unanswered questions about type 1 diabetes, based on the priorities of adults in the UK and Ireland.
When given to mice and pigs with type 1 diabetes, a new type of oral insulin developed with JDRF funding detects rising blood glucose and quickly lowers it to a safe level without causing hypos.
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
JDRF ambassador James Norton will read a CBeebies Bedtime Story this Diabetes Awareness Week to help young children understand type 1 and how it can be managed
The leading global type 1 diabetes charity, JDRF International (JDRF) is proud to unveil its new brand and name, Breakthrough T1D. The new name embodies its mission to cure and treat type 1 diabetes (T1D), while supporting everyone who lives with the condition.
Medtronic Diabetes have announced they are funding the biopharmaceutical company Arecor Therapeutics to develop a novel, highly concentrated, thermostable insulin, which will be specialised for use in implantable insulin pumps.
The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.
Two siblings who have unique changes in a key gene have given researchers new insights that could help lead to innovative new treatments in type 1 diabetes.
JDRF and Digibete have teamed up to create Coping with Diabetes, a new interactive support tool to help children and young people with type 1 look after their mental health and wellbeing.
A new test by Randox, developed with JDRF-funded researchers at the University of Exeter, is the first in the world to use genetics to quickly identify who is at high risk of developing type 1 diabetes.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
